ICN Galenika Cuts Stake in SPI Pharmaceuticals

ICN Galenika, a joint venture between a Yugoslav pharmaceutical company and SPI Pharmaceuticals Inc. in Costa Mesa, has reduced its stake in SPI to 3.8%, according to a filing with the Securities and Exchange Commission.

ICN Galenika sold 800,000 shares, or 4.4%, of SPI's common stock between Jan. 7 and March 3. The shares were sold at prices ranging from $25.47 to $30.57, according to the filing.

SPI owns 75% of ICN Galenika as part of a joint venture agreement.

Copyright © 2019, Los Angeles Times
EDITION: California | U.S. & World